APPLICATION
NDA014359
TYPE
NDA
ORIGINAL APPROVAL
1963-07-03
LATEST ACTION
1996-04-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
NEURAMATEDiscontinued
MEPROBAMATE 200MG · TABLET · ORAL
NEURAMATEDiscontinued
MEPROBAMATE 400MG · TABLET · ORAL
Approval history
1996-04-26Labeling · Supplement 30AP
1996-04-26Labeling · Supplement 22AP
1996-04-26Labeling · Supplement 20AP
1996-04-26Labeling · Supplement 29AP
1996-04-26Labeling · Supplement 35AP
1996-04-26Labeling · Supplement 27AP
1996-04-26Labeling · Supplement 19AP
1996-04-26Labeling · Supplement 25AP
1996-04-26Labeling · Supplement 17AP
1996-04-26Labeling · Supplement 31AP
1996-04-26Labeling · Supplement 21AP
1996-04-26Labeling · Supplement 52AP
1996-04-26Labeling · Supplement 28AP
1996-04-26Labeling · Supplement 26AP
1996-04-26Labeling · Supplement 32AP
1981-03-11Labeling · Supplement 50AP
1981-01-16Labeling · Supplement 49AP
1980-09-25Labeling · Supplement 48AP
1980-08-26Labeling · Supplement 47AP
1980-04-24Labeling · Supplement 46AP
1980-02-28Labeling · Supplement 45AP
1980-02-28Labeling · Supplement 43AP
1979-08-08Labeling · Supplement 42AP
1979-07-17Labeling · Supplement 41AP
1979-05-18Labeling · Supplement 40AP
1978-07-21Labeling · Supplement 38AP
1978-06-30Labeling · Supplement 37AP
1978-05-05Labeling · Supplement 36AP
1975-05-22Labeling · Supplement 18AP
1974-08-26Labeling · Supplement 16AP
1963-07-03Type 5 - New Formulation or New Manufacturer · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.